3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Cholangiocarcinoma
2
Liver Neoplasms
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Interventions
Gemcitabine
20
Fluorouracil
14
Cisplatin
10
Capecitabine
10
Leucovorin
8
durvalumab
6
Oxaliplatin
6
Erlotinib Hydrochloride
4
Sorafenib
3
Radiotherapy
3
trifluridine tipiracil drug combination
2
trametinib
2
regorafenib
2
pembrolizumab
2
olaparib
2
ceralasertib
2
Specimen Handling
2
Radiosurgery
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Magnetic Resonance Spectroscopy
2
Lapatinib
2
Irinotecan
2
Filgrastim
2
AZD 6244
2
zimberelimab
1
tremelimumab
1
titanium silicide
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
seribantumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Bile Duct Neoplasms
×
derazantinib
×
Clear all
NCT03230318
2023-12-19
FIDES-01
Basilea Pharmaceutica
Phase 2
Completed
148 enrolled
15 charts